US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Gastrointestinal Market Research Reports & Industry Analysis

RSS Feeds

Gastrointestinal Industry Research & Market Reports

3  4  5  6    8    10  11  12  
Germany Gastrointestinal Drugs Market Insights - 2015
3/14/2015 | published by: Fore Pharma
... includes gastrointestinal drugs market size estimates for 2014 in Germany, market size forecast for six years to 2020, drugs sales estimates, market share, market analysis by therapeutic sub-groups, and competitor analysis. This research helps executives ...  |  read more...
USD 1,380
UK Gastrointestinal Drugs Market Insights - 2015
3/14/2015 | published by: Fore Pharma
... includes gastrointestinal drugs market size estimates for 2014 in UK, market size forecast for six years to 2020, drugs sales estimates, market share, market analysis by therapeutic sub-groups, and competitor analysis. This research helps executives ...  |  read more...
USD 1,380
China Gastrointestinal Drugs Market Insights - 2015
3/14/2015 | published by: Fore Pharma
... includes gastrointestinal drugs market size estimates for 2014 in China, market size forecast for six years to 2020, drugs sales estimates, market share, market analysis by therapeutic sub-groups, and competitor analysis. This research helps executives ...  |  read more...
USD 1,380
Gastric Ulcers-API Insights, 2015
4/21/2015 | published by: DelveInsight
... the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Gastric Ulcers. The Report provides the India and China API Manufactures who are driving the ...  |  read more...
USD 1,250
Irritable Bowel Syndrome-API Insights, 2015
4/21/2015 | published by: DelveInsight
... clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Irritable Bowel Syndrome. The Report provides the India and China API Manufactures ...  |  read more...
USD 1,250
Peptic Ulcers-API Insights, 2015
4/21/2015 | published by: DelveInsight
... the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Peptic Ulcers. The Report provides the India and China API Manufactures who are driving the ...  |  read more...
USD 1,250
Gastritis-API Insights, 2015
4/21/2015 | published by: DelveInsight
... Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Gastritis. The Report provides the India and China API Manufactures who are driving the current API Market. DelveInsight’s ...  |  read more...
USD 1,250
Gastrointestinal Stromal Tumor (GIST)-API Insights, 2015
4/21/2015 | published by: DelveInsight
... report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Gastrointestinal Stromal Tumor (GIST). The Report provides the India ...  |  read more...
USD 1,250
Short Bowel Syndrome-API Insights, 2015
4/21/2015 | published by: DelveInsight
... clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Short Bowel Syndrome. The Report provides the India and China API Manufactures ...  |  read more...
USD 1,250
Global Gastrointestinal OTC Drugs Market 2015-2019
4/15/2015 | published by: TechNavio - Infiniti Research Ltd.
... regulatory agencies to ensure their safety and efficacy. Gastrointestinal OTC drugs can be bought off-the-shelf. Gastrointestinal OTC drugs are used for indications such as GERD, vomiting, constipation, diarrhea, and flatulence. Some of the OTC drugs ...  |  read more...
USD 2,500
Acid Indigestion / Heartburn/ Pyrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... phase III pipeline drugs and marketed drugs across the Acid Indigestion / Heartburn/ Pyrosis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs ...  |  read more...
USD 2,000
Gastritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... the Gastritis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Gastritis. ...  |  read more...
USD 2,000
Gastrointestinal Stromal Tumor (GIST)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... pipeline drugs and marketed drugs across the Gastrointestinal Stromal Tumor (GIST). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different ...  |  read more...
USD 2,000
Short Bowel Syndrome-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Short Bowel Syndrome. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Global Gastrointestinal Infrared Therapy Device Industry
11/2/2014 | published by: 9Dimen Research
... of Gastrointestinal Infrared Therapy Device industry, the main region including North American, Europe and Asia etc, and the main country including United States ,Germany ,Japan and China etc. The report firstly introduced Gastrointestinal Infrared Therapy ...  |  read more...
USD 2,850
Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015
1/21/2015 | published by: GlobalData
... report provides elemental information and data relating to the clinical trials on Irritable Bowel Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across ...  |  read more...
USD 2,500
PharmaPoint: Irritable Bowel Syndrome - US Drug Forecast and Market Analysis to 2023
12/31/2014 | published by: GlobalData
... not a life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies ...  |  read more...
USD 4,995
PharmaPoint: Irritable Bowel Syndrome - Japan Drug Forecast and Market Analysis to 2023
12/31/2014 | published by: GlobalData
... not a life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies ...  |  read more...
USD 4,995
PharmaPoint: Irritable Bowel Syndrome - Current and Future Players
12/31/2014 | published by: GlobalData
... with in-depth analysis on the companies in the rapidly growing Irritable Bowel Syndrome Market. The report identifies and analyses the key companies shaping and driving the global Irritable Bowel Syndrome market. The report provides insight ...  |  read more...
USD 2,995
Linzess (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
12/31/2014 | published by: GlobalData
... life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for ...  |  read more...
USD 3,495
Lotronex (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
12/31/2014 | published by: GlobalData
... life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for ...  |  read more...
USD 3,495
Eluxadoline (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
12/31/2014 | published by: GlobalData
... life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for ...  |  read more...
USD 3,495
Ibodutant (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
12/31/2014 | published by: GlobalData
... life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for ...  |  read more...
USD 3,495
Xifaxan (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
12/31/2014 | published by: GlobalData
... life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for ...  |  read more...
USD 3,495
Plecanatide (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
12/31/2014 | published by: GlobalData
... life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for ...  |  read more...
USD 3,495
3  4  5  6    8    10  11  12